You are here

Rare Diseases

How Covid-19 is changing rare diseases research

How Covid-19 is changing rare diseases research

MedCity News

Flag link:

Pharmacquired: What a surprise deal does for AstraZeneca and Alexion

Pharmacquired: What a surprise deal does for AstraZeneca and Alexion

BioPharma Dive

Flag link:

AstraZeneca to buy Alexion for $39B

AstraZeneca to buy Alexion for $39B

BioPharma Dive

Flag link:

FDA to expedite development of two Sanofi rare disease drugs

FDA to expedite development of two Sanofi rare disease drugs

Pharmaforum

Avalglucosidase alfa

Flag link:

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Endpoints

Arrowhead Pharmaceuticals

Flag link:

FDA seeks input on rare disease clinical trials network

FDA seeks input on rare disease clinical trials network

RAPS.org

clinical trials

Flag link:

With money flowing, Pliant Therapeutics heads to public well

With money flowing, Pliant Therapeutics heads to public well

Endpoints

Pliant Therapeutics

Flag link:

Takeda signs $882m rare disease alliance with Oxford biotech Evox

Takeda signs $882m rare disease alliance with Oxford biotech Evox

Pharmaforum

Evox Therapeutics

Flag link:

The biggest challenges facing rare disease pharma – and how the industry can tackle them

The biggest challenges facing rare disease pharma – and how the industry can tackle them

Pharmaforum

drug development

Flag link:

Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts

Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts

Fierce Pharma

Spark Therapeutics

Flag link:

Regeneron's bone disease drug delivers in phase 2, poised for FDA filing

Regeneron's bone disease drug delivers in phase 2, poised for FDA filing

Fierce Biotech

clinical trials

Flag link:

3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020

3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020

Yahoo/Zacks.com

Alzheimer's disease

Medical Marijuana

Flag link:

Drugmakers rebranding around oncology, rare diseases could provide 2020 preview

Drugmakers rebranding around oncology, rare diseases could provide 2020 preview

Fierce Pharma

Flag link:

Horizon looks to the future with massive San Francisco manufacturing, R&D plant

Horizon looks to the future with massive San Francisco manufacturing, R&D plant

Fierce Pharma

Horizon Therapeutics

drug manufacturing

Flag link:

Takeda sees cell, gene therapy in its future. Is it too late?

Takeda sees cell, gene therapy in its future. Is it too late?

Biopharma Dive

Flag link:

Rare Disease Clinical Trials: FDA Awards $15M in Grants

Rare Disease Clinical Trials: FDA Awards $15M in Grants

RAPS.org

clinical trials

Flag link:

Rare genetic disease company Homology raises $125M follow-on

Rare genetic disease company Homology raises $125M follow-on

BioCentury

Flag link:

Industry and Advocacy Groups Urge FDA to Allow More Real-World Data for Rare Disease Trials

Industry and Advocacy Groups Urge FDA to Allow More Real-World Data for Rare Disease Trials

BioSpace

real world data

Flag link:

How pharma can support doctors who treat rare diseases

How pharma can support doctors who treat rare diseases

Pharmaforum

Flag link:

Rare Disease Day: How the patient voice can tear down barriers

Rare Disease Day: How the patient voice can tear down barriers

Pharmaforum

Flag link:

Pages